Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Abstract
Patients with inflammatory bowel disease (IBD) have an increased risk of colon cancer. However, the immune cells and cytokines that mediate the transition from intestinal inflammation to cancer are poorly understood. We show that bacteria-induced colon cancer is accompanied by differential accumulation of IL-17(+)IL-22(+) colonic innate lymphoid cells (cILCs), which are phenotypically distinct from LTi and NK-22 cells, and that their depletion in mice with dysplastic inflammation blocks the development of invasive colon cancer. Analysis of the functional role of distinct Type 17 cytokines shows that although blockade of IL-17 inhibits some parameters of intestinal inflammation, reduction in dysplasia and colorectal cancer (CRC) requires neutralization of IL-22 indicating a unique role for IL-22 in the maintenance of cancer in this model. Mechanistic analyses showed that IL-22 selectively acts on epithelial cells to induce Stat3 phosphorylation and proliferation. Importantly, we could detect IL-22(+)CD3(+) and IL-22(+)CD3(−) cells in human CRC. Our results describe a new activity of IL-22 in the colon as a nonredundant mediator of the inflammatory cascade required for perpetuation of CRC, highlighting the IL-22 axis as a novel therapeutic target in colon cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although known to exert a tumor-promoting effect in colorectal cancer (Kirchberger et al., 2013; Wang et al., 2017)”
From Commensal Microbiota Promote Lung Cancer Development via γδ T Cells (2019) · cites this paper as Kirchberger et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039 · cited 1×
“…in many mouse models (Hue et al., 2006; Izcue et al., 2008), and its components IL-23R and Stat3 are not only associated with IBD susceptibility (Duerr et al., 2006; Barrett et al., 2008) but also involved in inflammation-associated cancer in the skin and colon (Langowski et al., 2006; Bollrath…”
BackgroundThe risk of colorectal cancer in ulcerative colitis: a meta-analysis
Eaden, J. A., Abrams, K. R., & Mayberry, J. F. (2001) · Gut · doi:10.1136/gut.48.4.526 · Cited by 2,959 · cited 1×
“In inflammatory bowel disease (IBD) patients, deranged inflammatory responses toward the intestinal microbiota increase the risk of colon cancer twofold (Eaden et al., 2001).”
BackgroundGenome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
the NIDDK IBD Genetics Consortium, Barrett, J. C., the Belgian-French IBD Consortium, the Wellcome Trust Case Control Consortium, Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. R., et al. (2008) · Nature Genetics · doi:10.1038/ng.175 · Cited by 2,593 · cited 1×
“…(Hue et al., 2006; Izcue et al., 2008), and its components IL-23R and Stat3 are not only associated with IBD susceptibility (Duerr et al., 2006; Barrett et al., 2008) but also involved in inflammation-associated cancer in the skin and colon (Langowski et al., 2006; Bollrath et al., 2009;…”
BackgroundLiang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330 · cited 8×
“It is now appreciated that a Type 17 cytokine expression signature is not restricted to Th-17 cells, and that cytokines such as IL-17 and IL-22 can be produced by unconventional T cell populations and more recently described RORtexpressing innate lymphoid populations (Pearson et al., 2012).”
BackgroundInfluentialCrypt stem cells as the cells-of-origin of intestinal cancer
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. (2009) · Nature · doi:10.1038/nature07602 · Cited by 2,166 · cited 1×
“IL-22 may also promote cancer through direct effects on intestinal epithelial stem cells, previously shown to be key precursors for intestinal cancer (Barker et al., 2009).”
BackgroundGrivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155 · cited 2×
“The role of Stat3 in colon cancer is well known but this has been attributed to activation by IL-6 and IL-11 (Ernst et al., 2008; Grivennikov et al., 2009).”
BackgroundFusobacterium nucleatum infection is prevalent in human colorectal carcinoma
Castellarin, M., Warren, R. L., Freeman, J. D., Dreolini, L., Krzywinski, M., Strauss, J., Barnes, R., Watson, P., Allen-Vercoe, E., Moore, R. A., et al. (2012) · Genome Research · doi:10.1101/gr.126516.111 · Cited by 2,043 · cited 1×
“Furthermore, certain species like the anaerobic Fusobacterium nucleatum were found to be associated with human CRC tissue (Castellarin et al., 2012; Kostic et al., 2012).”
BackgroundGenomic analysis identifies association of Fusobacterium with colorectal carcinoma
Kostic, A. D., Gevers, D., Pedamallu, C. S., Michaud, M., Duke, F., Earl, A. M., Ojesina, A. I., Jung, J., Bass, A. J., Tabernero, J., et al. (2012) · Genome Research · doi:10.1101/gr.126573.111 · Cited by 1,960 · cited 1×
“Furthermore, certain species like the anaerobic Fusobacterium nucleatum were found to be associated with human CRC tissue (Castellarin et al., 2012; Kostic et al., 2012).”
BackgroundInterleukin-22 mediates early host defense against attaching and effacing bacterial pathogens
Zheng, Y., Valdez, P. A., Danilenko, D. M., Hu, Y., Sa, S. M., Gong, Q., Abbas, A. R., Modrusan, Z., Ghilardi, N., de Sauvage, F. J., et al. (2008) · Nature Medicine · doi:10.1038/nm1720 · Cited by 1,921 · cited 8×
“IL-23 also drives colon cancer in an APC model, where it is induced in tumor-associated myeloid 928 Interleukin-22 in colon cancer | Kirchberger et al. (Reference numbers: 11/YH/0020 and 09/H0606/5) and informed written consent was given by all study patients.”
BackgroundInfluentialWu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812 · cited 3×
“Th17 cell infiltration was also found in animal models of colon cancer, such as the ApcMin model driven by the enterotoxigenic bacterium Bacteroides fragilis, where blockade of IL-17 decreased tumor incidence (Wu et al., 2009).”
Background
Cited by
Items 201–300 of 529
Innate lymphoid cells: New paradigm in immunology of inflammation
Kumar, V. (2013) · Immunology Letters · doi:10.1016/j.imlet.2013.11.003 · Cited by 64
Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia
de Weerdt, I., van Hoeven, V., Munneke, J. M., Endstra, S., Hofland, T., Hazenberg, M. D., & Kater, A. P. (2016) · Haematologica · doi:10.3324/haematol.2016.144725 · Cited by 55
Differentiation and function of group 3 innate lymphoid cells, from embryo to adult
van de Pavert, S. A., & Vivier, É. (2015) · International Immunology · doi:10.1093/intimm/dxv052 · Cited by 62
Cancer Immunoediting by Innate Lymphoid Cells
Wagner, M., & Koyasu, S. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.03.004 · Cited by 56
Huang, Q., Jacquelot, N., Preaudet, A., Hediyeh-zadeh, S., Souza-Fonseca-Guimarães, F., McKenzie, A. N. J., Hansbro, P. M., Davis, M. J., Mielke, L. A., Putoczki, T. L., et al. (2021) · Cancers · doi:10.3390/cancers13030559 · Cited by 53
“However, the role of ILC family members in CRC appears to be divergent, with NK cells required for anti-tumour immunity [12,24], while ILC1 and ILC3 are commonly linked to the promotion of CRC [9,21,29].”
BackgroundEmerging strategies for cancer immunoprevention
Roeser, J. C., Leach, S. D., & McAllister, F. (2015) · Oncogene · doi:10.1038/onc.2015.98 · Cited by 52
“In a murine model of bacteria induced-colon cancer, innate lymphoid cells have been shown to sustain tumorigenesis through production of interleukin-22 [129].”
BackgroundCD62L Is a Functional and Phenotypic Marker for Circulating Innate Lymphoid Cell Precursors
Bar‐Ephraïm, Y. E., Koning, J. J., Ruiz, E. B., Konijn, T., Mourits, V. P., Lakeman, K. A. M., Boon, L., Bögels, M., van Maanen, J. P., den Haan, J. M. M., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701153 · Cited by 61
Innate lymphoid cells in tissue homeostasis and diseases
Ignácio, A., Breda, C. N. D. S., & Câmara, N. O. S. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i23.979 · Cited by 59
TREM-1 promotes intestinal tumorigenesis
Saurer, L., Zysset, D., Rihs, S., Mager, L. F., Gusberti, M., Simillion, C., Lugli, A., Zlobec, I., Krebs, P., & Mueller, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-14516-4 · Cited by 55
Cruel to Be Kind: Epithelial, Microbial, and Immune Cell Interactions in Gastrointestinal Cancers
Shalapour, S., & Karin, M. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082019-081656 · Cited by 54
“In addition, AhR-induced IL-22 production by ILCs drives secretion of the antimicrobial peptides lipocalin-2, S100A8, and S100A9, which provide protection from translocating microbes (103, 104), as well as Candida albicans (102).”
InfluentialStat3: Friend or Foe in Colitis and Colitis-associated Cancer?
Han, J., & Theiss, A. L. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000180 · Cited by 57
“In addition, IL-22 activation of epithelial Stat3 has been identified as a mediator of development and progression to CAC in a bacteria-induced model, distinct from the action of IL-6.(35) IL-22 induces hyperproliferation of epithelial cells during chronic colitis and therefore could perpetuate cancer through activati…”
BackgroundMisiorek, J. O., Lähdeniemi, I. A. K., Nyström, J. H., Paramonov, V. M., Gullmets, J., Saarento, H., Rivero‐Müller, A., Husøy, T., Taimen, P., & Toivola, D. M. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw063 · Cited by 51
“IL-22 is known to stimulate proliferation as well as the production of antimicrobial peptides and proteins protecting tissue via the signal transducer and activator of transcription 3 (STAT3) transcription factor in epithelial cells (22,24,25).”
BackgroundOrchestration of intestinal homeostasis and tolerance by group 3 innate lymphoid cells
Penny, H. A., Hodge, S. H., & Hepworth, M. R. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0687-8 · Cited by 50
The roles for innate lymphoid cells in the human immune system
Mazzurana, L., Rao, A., Acker, A. V., & Mjösberg, J. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0688-7 · Cited by 61
“production in the gut was also linked to the formation of tumors [67].”
BackgroundFriend or Foe? The Ambiguous Role of Innate Lymphoid Cells in Cancer Development
Mattner, J., & Wirtz, S. J. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.10.004 · Cited by 52
Wang, J., Wang, P., Tian, H., Tian, F., Zhang, Y., Zhang, L., Gao, X., & Wang, X. (2018) · Innate Immunity · doi:10.1177/1753425918785016 · Cited by 51
“AhR-mediated IL22 production from adaptive and innate cells normally confers protection from bacterial infections and wound healing.(25) Here, we found that antibiotic treatment led to reduced AhR levels and decreased IL-22 and phosphorylation Stat3 levels in ileal tissues, which are downstream targets of AhR and play…”
BackgroundLoyon, R., Jary, M., Salomé, B., Gomez‐Cadena, A., Galaine, J., Kroemer, M., Romero, P. J., Trabanelli, S., Adotévi, O., Borg, C., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02121 · Cited by 54
Doulabi, H., Rastin, M., Shabahangh, H., Maddah, G., Abdollahi, A., Nosratabadi, R., Esmaeili, S., & Mahmoudi, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.147 · Cited by 52
Innate lymphoid cells and cancer: Role in tumor progression and inhibition
Yuan, X., Rasul, F., Nashan, B., & Sun, C. (2021) · European Journal of Immunology · doi:10.1002/eji.202049033 · Cited by 48
Role of Inflammation in Pathophysiology of Colonic Disease: An Update
Nasef, N. A., & Mehta, S. Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134748 · Cited by 49
The IL-22–oncostatin M axis promotes intestinal inflammation and tumorigenesis
Cineus, R., Luo, Y., Saliutina, M., Manna, S., Cancino, C., Blázquez, L. V., Wang, L., Bösel, D., Abdelrahman, A., Klementowicz, J. E., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02149-z · Cited by 50
“…also been shown to play a double-edged role in CAC; dysregulated or sustained IL-22 expression (as occurs in the absence of IL-22BP) can promote tumorigenesis in AOM/DSS-and bacteria-induced colon cancer models, but it can also promote protective DNA damage responses in the epithelium 19,21,39 .”
The Interplay Between Innate Lymphoid Cells and the Tumor Microenvironment
Ducimetière, L., Vermeer, M., & Tugues, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02895 · Cited by 51
“In humans, the levels of IL-17 appear to be upregulated in colorectal cancer patients, where they associate to poor prognosis (35, 129, 130).”
BackgroundIL22BP Mediates the Antitumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans
Kempski, J., Giannou, A. D., Riecken, K., Zhao, L., Steglich, B., Lücke, J., Pérez, L. G., Karstens, K.-F., Woestemeier, A., Nawrocki, M., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.033 · Cited by 48
Endharti, A. T., Wulandari, A. R., Listyana, A., Norahmawati, E., & Permana, S. (2016) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1345-0 · Cited by 53
“A prominent cell cycle arrest at S phase was noted upon treatment with quercetin [27].”
BackgroundIL10R2 Overexpression Promotes IL22/STAT3 Signaling in Colorectal Carcinogenesis
Khare, V., Paul, G., Movadat, O., Frick, A. P., Jambrich, M., Krnjic, A., Marian, B., Wrba, F., & Gasché, C. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0031 · Cited by 41
“Interestingly, simultaneous presence of both receptor subunits (IL22R1 and IL10R2) was not observed in CAC (displaying IL10R2 similar as in IBD).”
BackgroundInfluentialInnate Lymphoid Cells in Cancer
Vallentin, B., Barlogis, V., Pipéroglou, C., Cypowyj, S., Zucchini, N., Chéné, M., Navarro, F., Farnarier, C., Vivier, É., & Vely, F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0222 · Cited by 47
“Indeed, the production of IL22 by NCR ILC3 is a key factor underlying cancermaintenance in amousemodel of colon cancer induced by bacteria (47).”
BackgroundInnate Lymphoid Cells (ILCs) as Mediators of Inflammation, Release of Cytokines and Lytic Molecules
Elemam, N., Hannawi, S., & Maghazachi, A. (2017) · Toxins · doi:10.3390/toxins9120398 · Cited by 41
“However, sustained IL-22 and epithelial proliferation may promote tumorigenecity [100], where ILC3s have been identified to be present in high proportions in non-small cell lung cancer (NSCLC) tumor tissues [8], as well as colorectal cancer [101].”
Xuan, X., Zhou, J., Tian, Z., Lin, Y., Song, J. J., Ruan, Z., Ni, B., Zhao, H., & Yang, W. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02160-5 · Cited by 43
The unique role of innate lymphoid cells in cancer and the hepatic microenvironment
Curio, S., & Belz, G. T. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00901-1 · Cited by 43
“ILC3s can promote inflammation and tumorigenesis by secreting IL-17A and IL-22 in response to IL-23 [143, 144].”
BackgroundCrosstalk between the gut microbiota and innate lymphoid cells in intestinal mucosal immunity
Guo, Y., Liu, Y., Rui, B., Lei, Z., Ning, X., Liu, Y., & Li, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1171680 · Cited by 53
Grizzi, F., Basso, G., Borroni, E. M., Cavalleri, T., Bianchi, P. P., Štifter, S., Chiriva‐Internati, M., Malesci, A., & Laghi, L. (2018) · Inflammation Research · doi:10.1007/s00011-017-1128-1 · Cited by 45
“have reported IL-22 axis as a novel therapeutic target in colon cancer [143].”
BackgroundRad, H. F., Tahmasebi, H., Javani, S., Hemati, M., Zakerhamidi, D., Hosseini, M., Alibabaei, F., Banihashemian, S. Z., Oksenych, V., & Eslami, M. (2024) · Biomedicines · doi:10.3390/biomedicines12122776 · Cited by 46
Innate Lymphoid Cells in Tumor Immunity
van Beek, J. J. P., Martens, A. W. J., Bakdash, G., & de Vries, I. J. M. (2016) · Biomedicines · doi:10.3390/biomedicines4010007 · Cited by 42
“IL-22 produced by ILC3s may play an important role in human CRC as well, as both IL-22+ CD3+ and IL-22+ CD3 ́ cells can be detected within CRC tumors [97].”
Bi, Y., Cao, J., Jin, S., Lv, L., Li, Q., Liu, F., Geng, J., & Yu, Y. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2663-8 · Cited by 41
Type 3 cytokines in liver fibrosis and liver cancer
Molina, M. F., Abdelnabi, M. N., Fabre, T., & Shoukry, N. H. (2019) · Cytokine · doi:10.1016/j.cyto.2018.07.028 · Cited by 39
Interleukin‐22 and intestinal homeostasis: Protective or destructive?
Shohan, M., Dehghani, R., Khodadadi, A., Dehnavi, S., Ahmadi, R., Joudaki, N., Houshmandfar, S., Shamshiri, M., Shojapourian, S., & Bagheri, N. (2020) · IUBMB Life · doi:10.1002/iub.2295 · Cited by 41
“The promoting role of IL-22 in CRC development may be due to the STAT3 oncogenic activity.(127,128) In another study, in antigen presenting cell (APC) min + mice model, the role of IL-22BP or IL22RA2 as an IL-22 inhibitor in colon tumorigenesis was investigated.”
BackgroundGriffith, B. D., & Frankel, T. L. (2024) · Cancers · doi:10.3390/cancers16030472 · Cited by 50
“ILC3s are generally seen as pro-tumorigenic, as suggested by studies in both hepatocellular carcinoma [68] and colorectal cancer [69], in part due to their ability to induce tumor cell signal transducer and activator of transcription 3 (STAT3) activation and cellular proliferation [69,70].”
BackgroundShen, G., Wang, Q., Li, Z., Xie, J., Han, X., Wei, Z., Zhang, P., Zhao, S., Wang, X., Huang, X., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.96338 · Cited by 43
“In a colitis-associated carcinoma mouse model, IL-22 induced epithelial signal transducer and activator of transcription 3 (STAT-3) phosphorylation and proliferation, thereby facilitating cancer development [96].”
BackgroundInfluentialThe Role of IL-22 in Viral Infections: Paradigms and Paradoxes
Brias, S. G., Stack, G., Stacey, M. A., Redwood, A., & Humphreys, I. R. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00211 · Cited by 43
“Furthermore, recent studies using mouse models of colon cancer have shown that IL-22 produced by CD4+ T cells acts upon cancer cells to activate STAT3 and promote the expression of the histone 3 lysine 79 (H3K79) methyltransferase DOT1L, which induces key cancer stem cell genes that contribute to tumor progression (34…”
BackgroundHelper-like innate lymphoid cells and cancer immunotherapy
Crinier, A., Vivier, É., & Bléry, M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.04.002 · Cited by 41
Pellegrini, C., Orlandi, A., Costanza, G., Stefani, A. D., Piccioni, A., Cesare, A. D., Chiricozzi, A., Ferlosio, A., Peris, K., & Fargnoli, M. C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183415 · Cited by 41
Interleukin-17 and type 17 helper T cells in cancer management and research
Housseau, F., Geis, A. L., Orberg, E. T., & Llosa, N. J. (2014) · ImmunoTargets and Therapy · doi:10.2147/itt.s56529 · Cited by 42
“41 A similar functional plasticity demonstrated by the Treg allows skewing of Foxp3 + Tregs toward Th17 in the presence of IL-1 β or IL-23.”
BackgroundSubramaniam, R., Mizoguchi, A., & Mizoguchi, E. (2016) · Cancer Research Frontiers · doi:10.17980/2016.1 · Cited by 46
“attenuated CAC development compared to IL-17 inhibition (100).”
Plastic Heterogeneity of Innate Lymphoid Cells in Cancer
Wagner, M., Moro, K., & Koyasu, S. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.03.008 · Cited by 37
Myeloid derived suppressor cells in tumor microenvironment: Interaction with innate lymphoid cells
Tumino, N., Fiore, P. F., Pelosi, A., Moretta, L., & Vacca, P. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101668 · Cited by 49
Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias
Pietra, G., Vitale, C., Pende, D., Bertaina, A., Moretta, F., Falco, M., Vacca, P., Montaldo, E., Cantoni, C., Mingari, M. C., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1744-y · Cited by 37
“In this context, in a murine model, IL-22 produced by T cells and ILC3 contributed to the development of colon cancer [23].”
Innate lymphoid cells, mediators of tissue homeostasis, adaptation and disease tolerance
Branzk, N., Gronke, K., & Diefenbach, A. (2018) · Immunological Reviews · doi:10.1111/imr.12718 · Cited by 43
Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
Shen, P., Han, L., Ba, X., Qin, K., & Tu, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.678409 · Cited by 37
“In a mouse model of colon cancer, reduction of IL-22 production by ILC3 impaired the progression of gastrointestinal cancers (Kirchberger et al., 2013).”
BackgroundTNF hampers intestinal tissue repair in colitis by restricting IL-22 bioavailability
Ninnemann, J., Winsauer, C., Bondareva, M. A., Kühl, A. A., Lozza, L., Durek, P., Lissner, D., Siegmund, B., Kaufmann, S. H. E., Mashreghi, M., et al. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00506-x · Cited by 38
Innate lymphoid cells: new players in IL-17-mediated antifungal immunity
Gladiator, A., & LeibundGut-Landmann, S. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003763 · Cited by 35
“been implicated in chronic situations of intestinal inflammation in humans and mice and in the progression toward bacteria-induced colon cancer in a mouse model [13,14,29].”
BackgroundThe Yin and Yang of Innate Lymphoid Cells in Cancer
Carrega, P., Campana, S., Bonaccorsi, I., & Ferlazzo, G. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.06.003 · Cited by 37
IL-15 suppresses colitis-associated colon carcinogenesis by inducing antitumor immunity
Bahri, R., Pateras, I. S., D’Orlando, O., Goyeneche-Patino, D. A., Campbell, M., Polansky, J. K., Sandig, H., Papaioannou, M. D., Evangelou, K., Foukas, P. G., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.1002721 · Cited by 40
Chen, X., Li, L., Khan, M. N., Shi, L., Wang, Z., Zheng, F., Gong, F., & Fang, M. (2016) · Innate Immunity · doi:10.1177/1753425916669862 · Cited by 36
“under normal circumstances, but high levels of IL-22 and IL-17 also cause colitis or aggravate inflammation during bacterial infection or intestinal injury.(40) In our experiment, the frequencies of IL-22- or IL-17-positive ILC3s increased in the injured colon tissues.”
BackgroundOverstreet, A.-M. C., LaTorre, D. L., Close, L. A., Murphy, S. F., Rhee, L., Boger-May, A. M., Adlaka, K. R., Iverson, A. M., Bakke, D., Weber, C. R., et al. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0051-2 · Cited by 35
Tosti, N., Cremonesi, E., Governa, V., Basso, C., Kancherla, V., Coto‐Llerena, M., Amicarella, F., Weixler, B., Däster, S., Sconocchia, G., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0934 · Cited by 35
“IL22 also plays a role in IBDpathogenesis, potentially resulting in colorectal cancer outgrowth (37, 38).”
BackgroundLuci, C., Bihl, F., Bourdely, P., Khou, S., Popa, A., Meghraoui, A., Vermeulen, O., Elaldi, R., Poissonnet, G., Sudaka, A., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.03.018 · Cited by 35
“IL-17-secreting cells resemble ILC3 previously shown to promote inflammation at mucosal surfaces (Chan et al., 2014; Kirchberger et al., 2013).”
BackgroundIshihara, Y., Kado, S. Y., Bein, K. J., He, Y., Pouraryan, A. A., Urban, A., Haarmann‐Stemmann, T., Sweeney, C. A., & Vogel, C. F. A. (2022) · Frontiers in Toxicology · doi:10.3389/ftox.2021.787360 · Cited by 49
“, 2020) including colon cancer (Huber et al., 2012; Kirchberger et al., 2013; Markota et al., 2018; DmitrievaPosocco et al., 2019; Arshad et al., 2020) and breast cancer (Kim et al.”
BackgroundThe role of group 3 innate lymphoid cell in intestinal disease
Li, M., Wang, Z., Jiang, W., Lu, Y., & Zhang, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1171826 · Cited by 43
Innate immune cells: Key players of orchestra in modulating tumor microenvironment (TME)
Sadeghi, M., Dehnavi, S., Sharifat, M., Amiri, A. M., & Khodadadi, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27480 · Cited by 40
“It has been shown that IL-17 and IL-22 produced by ILC3s induce tumor progression in colon cancer [122].”
BackgroundRegulation of tumor angiogenesis by the crosstalk between innate immunity and endothelial cells
Ebeling, S., Kowalczyk, A., Pérez-Vázquez, D., & Mattiola, I. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1171794 · Cited by 39
Yazdani, R., Sharifi, M., Shirvan, A. S., Azizi, G., & Ganjalıkhani-Hakemi, M. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.09.006 · Cited by 38
Costa, D. B. V., Francescone, R., Posocco, D. F., Hou, V., Dmitrieva, O., Hensley, H. H., de Carvalho, J. E., Pilli, R. A., & Grivennikov, S. I. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw112 · Cited by 35
“These cytokines are induced by DSS and other inflammatory stimuli, present in samples from patients with active IBD and implicated in the development and growth of CRC (26,32-35).”
BackgroundGroup 3 ILCs: Peacekeepers or Troublemakers? What's Your Gut Telling You?!
Pantazi, E. D., & Powell, N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00676 · Cited by 40
“Importantly, IL-22, but not IL-17, was necessary for cancer maintenance (74).”
BackgroundHide and seek: Plasticity of innate lymphoid cells in cancer
Bald, T., Wagner, M., Gao, Y., Koyasu, S., & Smyth, M. J. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.04.001 · Cited by 35
The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer
McCuaig, S., Barras, D., Mann, E. H., Friedrich, M., Bullers, S. J., Janney, A., Garner, L. C., Domingo, E., Koelzer, V. H., Delorenzi, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1086 · Cited by 42
Becker, W., Alrafas, H. R., Wilson, K. M., Miranda, K., Culpepper, C. D., Chatzistamou, I., Cai, G., Nagarkatti, M., & Nagarkatti, P. S. (2020) · iScience · doi:10.1016/j.isci.2020.101504 · Cited by 39
Cell-intrinsic view of the aryl hydrocarbon receptor in tumor immunity
Dean, J. W., & Zhou, L. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.01.008 · Cited by 33
Crosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor Microenvironment
Flores‐Borja, F., Irshad, S., Gordon, P., Wong, F., Sheriff, I., Tutt, A. N. J., & Ng, T. (2016) · Journal of Immunology Research · doi:10.1155/2016/7803091 · Cited by 34
“Using well-established models of bacteriainduced colon cancer and antibody-based cell depletion and cytokine neutralization protocols, the authors concluded that IL-17 and IL-22 produced by colonic ILC3 contribute to inflammation and tumor development, with an additional role for IL-22 to perpetuate the cancerous stat…”
Krieg, C., Weber, L. M., Fosso, B., Marzano, M., Hardiman, G., Olcina, M. M., Domingo, E., Aidy, S. E., Mallah, K., Robinson, M. D., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004717 · Cited by 30
“80 This finding is particularly interesting in light of our RNA-Seq data showing significantly higher expression of il-22ra2 in the polyps of APC Min/+ /C3aR−/− mice compared with APC Min/+ mice.”
The role of Th22 cells, from tissue repair to cancer progression
Doulabi, H., Masoumi, E., Rastin, M., Azarnaminy, A. F., Esmaeili, S., & Mahmoudi, M. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155749 · Cited by 38
Cheng, H., Jin, C., Wu, J., Zhu, S., Liu, Y., & Chen, J. (2017) · Protein & Cell · doi:10.1007/s13238-017-0379-5 · Cited by 37
“On the other hand, IL-22 activates the STAT3 cascade to enhance tumor generation (Kirchberger et al., 2013).”
Langerhans Cells Facilitate UVB-Induced Epidermal Carcinogenesis
Lewis, J. M., Bürgler, C. D., Freudzon, M., Golubets, K., Gibson, J. F., Filler, R. B., & Girardi, M. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.207 · Cited by 32
“Moreover, IL-22-producing ILCs were shown to be the principal drivers of dysplasia in a model of inflammatory bowel disease-associated colorectal cancer (Kirchberger et al., 2013).”
BackgroundLoyon, R., Picard, E., Mauvais, O., Queiroz, L., Mougey, V., Pallandre, J., Galaine, J., Mercier‐Letondal, P., Kellermann, G., Chaput, N., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501147 · Cited by 30
“Indeed, colon cancer is accompanied by accumulation of IL-17IL-22 ILC3, and its depletion in mice blocks the development of invasive colon cancer (52).”
Programmed Cell Death-1 Receptor (PD-1)-Mediated Regulation of Innate Lymphoid Cells
Mallett, G., Laurence, A. D. J., & Amarnath, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112836 · Cited by 32
“ILC3s are activated by cytokines such as IL-23 and are efficient at inducing anti-bacterial responses through the production of cytokines such as IL-17 and IL-22.”
BackgroundInteractions between the intestinal microbiota and innate lymphoid cells
Chen, V. L., & Kasper, D. L. (2013) · Gut Microbes · doi:10.4161/gmic.27289 · Cited by 34
Regulation of intestinal health and disease by innate lymphoid cells
Sonnenberg, G. F. (2014) · International Immunology · doi:10.1093/intimm/dxu052 · Cited by 32
Innate lymphoid cells as regulators of the tumor microenvironment
Tugues, S., Ducimetière, L., Friebel, E., & Becher, B. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.03.002 · Cited by 32
Hitting More Birds with a Stone: Impact of TGF-β on ILC Activity in Cancer
Fionda, C., Stabile, H., Cerboni, C., Soriani, A., Gismondi, A., Cippitelli, M., & Santoni, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010143 · Cited by 35
“Similarly to the type 1 and 2 ILCs, also for ILC3s pro- and anti-tumor functions have been reported [94,95].”
BackgroundMahmood, S., Upreti, D., Sow, I., Alamri, A., Nandagopal, S., & Kung, S. K. P. (2015) · Immunotherapy · doi:10.2217/imt.14.122 · Cited by 29
Complexity of cytokine network regulation of innate lymphoid cells in protective immunity
Seillet, C., Belz, G. T., & Mielke, L. A. (2014) · Cytokine · doi:10.1016/j.cyto.2014.06.002 · Cited by 32
“IL-22 also appears to critically regulate tumorigenesis in the colon [95,96].”
BackgroundMortara, L., Benest, A. V., Bates, D. O., & Noonan, D. M. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.009 · Cited by 30
Pennel, K. A. F., Park, J. H., McMillan, D., Roseweir, A. K., & Edwards, J. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.11.013 · Cited by 30
Innate lymphoid cells in intestinal cancer development
Atreya, I., Kindermann, M., & Wirtz, S. J. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.02.001 · Cited by 29
Pleiotropic Role and Bidirectional Immunomodulation of Innate Lymphoid Cells in Cancer
An, Z., Flores‐Borja, F., Irshad, S., Deng, J., & Ng, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03111 · Cited by 31
From inflammatory bowel disease to colorectal cancer: what’s the role of miRNAs?
Vaghari‐Tabari, M., Targhazeh, N., Moein, S., Qujeq, D., Alemi, F., Majidina, M., Younesi, S., Asemi, Z., & Yousefi, B. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02557-3 · Cited by 30
“However, IL-22 can enhance STAT3 signaling in epithelial cells, increase proliferation, and play a role in colorectal cancer development [50].”
BackgroundAcute blockade of IL-25 in a colitis associated colon cancer model leads to increased tumor burden
Thelen, T. D., Green, R. M., & Ziegler, S. F. (2016) · Scientific Reports · doi:10.1038/srep25643 · Cited by 29
Feng, J., Jin, Y., Peng, J., Wei, L., Cai, Q., Yan, Z., Lai, Z., & Lin, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.7244 · Cited by 29
“The ability of immune cells to control cancer cell proliferation is mostly dependent on cytokines, which can directly target CRC cells, as well as contribute to the abnormal activation of various signaling pathways (40,47-51).”
Goc, J., Hepworth, M. R., & Sonnenberg, G. F. (2015) · International Immunology · doi:10.1093/intimm/dxv056 · Cited by 29
Human ILC3 Exert TRAIL-Mediated Cytotoxicity Towards Cancer Cells
Siegler, J.-J., Correia, M. P., Hofman, T., Prager, I., Birgin, E., Rahbari, N. N., Watzl, C., Stojanovic, A., & Cerwenka, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.742571 · Cited by 31
“It has been shown that ILC3s can both promote and inhibit tumor growth (18, 19).”
BackgroundRole of innate lymphoid cells in obesity and metabolic disease (Review)
Saetang, J., & Sangkhathat, S. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8038 · Cited by 38
“It has also been proposed that IL-22-producing CCR6 - NKp46 + ILC3s have an impact on the resistance to bacterial invasion in the colitis model (94,95), and modulate eosinophil infiltration and lymphocyte invasion in allergic airway hyperreactivity (AHR) in the lung (96).”
ILC regulation of T cell responses in inflammatory diseases and cancer
Warner, K., & Ohashi, P. S. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101284 · Cited by 29
An Overview of the Role of Innate Lymphoid Cells in Gut Infections and Inflammation
Sedda, S., Marafini, I., Figliuzzi, M. M., Pallone, F., & Monteleone, G. (2014) · Mediators of Inflammation · doi:10.1155/2014/235460 · Cited by 31
“In this context, it is noteworthy that IL-22 produced by ILCs facilitates the growth of cancer cells through a STAT3-dependent mechanism in a bacteriadriven mouse model of colorectal cancer [55].”
BackgroundGu, T., Jesus, M. D., Gallagher, H. C., Burris, T. P., & Egilmez, N. K. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1319027 · Cited by 29
“Separately, others have shown that the TH17 cytokines IL-17 and IL-22 can directly stimulate epithelial cell proliferation and tumor progression.(3,4) Taken together these findings suggest that the myeloid cell-T-cell axis represents an attractive target for therapy of inflammatory cancer.”
BackgroundNatural Compounds Targeting the Autophagy Pathway in the Treatment of Colorectal Cancer
Du, Y.-X., Mamun, A. A., Lü, A., & Zhang, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087310 · Cited by 26
Таширева, Л. А., Михайлович, П. В., Манских, В. Н., Denisov, E. V., Savelieva, O. E., Кайгородова, Е. В., & Zavyalova, M. V. (2017) · Biochemistry (Moscow) · doi:10.1134/s0006297917050029 · Cited by 31
Kim, E., Choi, B., Kim, J.-E., Park, S.-O., Kim, S., & Chang, E. (2020) · Cells · doi:10.3390/cells9010131 · Cited by 28
“Of note, the ablation of the IL‐22 pathway via an endogenous antagonist, IL‐22‐binding protein, suppressed tumorigenesis in a genetic model [17] and another study has reported that blocking IL‐22 which was locally produced by innate lymphoid cells inhibits colorectal tumors in the mouse [18].”
BackgroundCui, G., Wang, Z., Liu, H., & Pang, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1057181 · Cited by 28
Emanuel, E., Arifuzzaman, M., & Artis, D. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.02.004 · Cited by 27
Shahid, A., & Bharadwaj, M. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.07.001 · Cited by 25
Innate Lymphoid Cells in Tissue Homeostasis and Disease Pathogenesis
Kim, J., Ryu, S., & Kim, H. Y. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0053 · Cited by 26
“Moreover, ILC3s help rehabilitate intestinal epithelium that has been damaged (for example by chemotherapy) by secreting IL-22 (Hazenberg et al., 2019): this induces IL-22 receptor-expressing intestinal stem cells to regenerate the epithelial cells (Wolk et al., 2004).”
Background
Metadata
- Authors
- Kirchberger, S., Royston, D. J., Boulard, O., Thornton, E., Franchini, F., Szabady, R. L., Harrison, O., & Powrie, F.
- Affiliations
- John Radcliffe Hospital (GB)
- University of Oxford (GB)
- Corresponding author
- Powrie, Fiona
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-04-15
- Volume
- 210
- Issue
- 5
- Pages
- 917-931
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3646494
- OpenAlex
- W2124499950
- Cited by
- 529
- References
- 52
- Citations by year
- 2026: 18 · 2025: 12 · 2024: 24 · 2023: 33 · 2022: 39 · 2021: 34 · 2020: 54 · 2019: 51 · 2018: 42 · 2017: 55 · 2016: 48 · 2015: 54 · 2014: 50 · 2013: 12
- FWCI
- 30.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- Funders
- Royal College of Pathologists of Australasia
- Wellcome Trust (095688/Z/11/Z, 095688)
- Cancer Research UK (A7297, A11663)
- National Institute for Health and Care Research
- European Commission (223151)
- Jean Shanks Foundation
- Austrian Science Fund
- Genentech
- Biotechnology and Biological Sciences Research Council (BB/I005609/1)
- NIHR Oxford Biomedical Research Centre
- UCB Celltech
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- colon cancer, IL-22, IL-17, innate lymphoid cells, inflammatory bowel disease, STAT3 phosphorylation, epithelial cell proliferation, therapeutic target
- MeSH terms
- Interleukin-22, Animals, Antigens, Ly, Cell Transformation, Neoplastic, Colitis, Colon, Colonic Neoplasms, Disease Models, Animal, Epithelial Cells, Humans, Interleukins, Lymphocytes, Phosphorylation, CD4 Antigens, Gene Expression Regulation, Neoplastic, Helicobacter, Disease Progression, Cell Lineage, STAT3 Transcription Factor, Mice, Natural Cytotoxicity Triggering Receptor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.